Nitrogen-Fused Ring CRTH2 Antagonists for Selective Allergy Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current medications lack effective antagonism towards CRTH2 receptors, which are involved in allergic diseases such as asthma, allergic rhinitis, and eosinophilic granulocyte-related conditions, with existing compounds like Ramatroban having low selectivity and adverse reactions.
Innovation Solution
Development of nitrogen-containing fused ring compounds as CRTH2 antagonists with high selectivity and activity, optimized physical-chemical properties, and novel structures to enhance druggability, as represented by specific compounds following general formula (I) and their pharmaceutically acceptable salts.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Ramatroban is used as CRTH2 antagonist, then platelet activation effect is improved, but selectivity is worsened and adverse reactions occur
Solution Approach 1:
The patent applies local quality by designing specific functional groups and substitution patterns at particular positions of the fused ring structure. The nitrogen-containing fused ring core with specific substituents at defined positions creates localized interaction zones that selectively bind to CRTH2 receptor while avoiding off-target thromboxane A2 receptors, thus achieving high selectivity without sacrificing antagonism effect.
Solution Approach 2:
The patent employs parameter changes by systematically varying structural parameters including the type of nitrogen atoms in the fused ring system, the nature and position of substituents (R1-R6 groups), and molecular configuration. These parameter optimizations tune the binding affinity and selectivity profile, enabling compounds to achieve potent CRTH2 antagonism with minimal cross-reactivity to other receptors.
2Reliability
If existing CRTH2 antagonists are developed, then therapeutic effect is improved, but safety profile is worsened due to adverse reactions
Solution Approach 1:
The patent converts the potential harm of off-target receptor binding into benefit by carefully designing the molecular structure to exploit specific structural features of the CRTH2 receptor binding pocket. The nitrogen-containing fused ring system with particular substitution patterns is engineered to form selective interactions with CRTH2 amino acid residues, transforming what could be non-specific binding into highly selective therapeutics with improved safety profiles.
Solution Approach 2:
The patent introduces the nitrogen-containing fused ring compounds as intermediary structures that mediate selective interaction between the therapeutic agent and CRTH2 receptor. These compounds act as precise molecular intermediaries that bridge the gap between desired therapeutic effect and safety, by providing a structural platform that selectively engages CRTH2 while avoiding other biological targets.
3Reliability
If novel compound structures are designed, then selectivity and activity are improved, but manufacturing complexity may increase
Solution Approach 1:
The patent applies segmentation by dividing the complex molecular structure into distinct functional modules: the nitrogen-containing fused ring core structure and various substituent groups (R1-R6). This modular design allows each segment to be optimized independently for selectivity and activity, while the overall assembly maintains manageable complexity through systematic structure-activity relationship principles.
Solution Approach 2:
The patent employs universality by designing the nitrogen-containing fused ring core as a universal scaffold that can accommodate multiple different substituent patterns. This multi-functional core structure serves as a platform for generating multiple analogs with varying selectivity and activity profiles, reducing the need to develop entirely new complex structures for different therapeutic indications.
Data Source
AI summary
The present application relates to nitrogen-containing fused ring compounds shown by general formula (I), a pharmaceutically acceptable salt thereof and a stereoisomer thereof as CRTH2 antagonist, wherein X1, X2, X3, X4, X5, W, X, Y, L1, L2, L3, A, B are as defined in the description; the present application further relates to a method for preparing the compounds, a pharmaceutical formulation and a pharmaceutical composition comprising the compounds, a use of the compounds for the manufacture of a medicament for the treatment and/or prevention of diseases related to activity of CRTH2.